In particular, the yellow subthreshold micropulse laser has been explored as a possible therapeutic option for diabetic macular edema and RVO, thus lowering the financial burden of repeated anti-VEGF injections and maintaining or improving morpho-functional outcomes [76,77]. The gene discussed is VEGFA; the disease is diabetic macular edema.